Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Semler (SMLR) To Contact Him Directly To Discuss Their Options If you purchased or acquired Semler Scientific securities between March 10, 2021 and April 15, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 10, 2025 (GLOBE NEWSWIRE) -- What’s Happenin ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Semler Scientific, Inc. due to alleged violations of federal securities laws, particularly concerning undisclosed investigations by the DOJ and misleading public statements [1][2]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses in Semler Scientific between March 10, 2021, and April 15, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Semler Scientific, with a deadline of October 28, 2025, for investors to seek the role of lead plaintiff [1][4]. - The complaint alleges that Semler Scientific and its executives failed to disclose a material investigation by the DOJ regarding violations of the False Claims Act [2]. Group 2: Financial Impact and Stock Performance - Semler Scientific's 2024 annual report revealed that initial settlement discussions with the DOJ began on February 11, 2025, but were ceased on the same day, indicating potential risks of a civil lawsuit [3]. - Following the disclosure of the DOJ investigation, Semler Scientific's stock fell over 9% on the next trading day [3]. Group 3: Participation and Whistleblower Information - Any member of the putative class can move the court to serve as lead plaintiff or remain an absent class member, with no impact on their ability to share in any recovery [4]. - The firm encourages whistleblowers, former employees, and shareholders with information regarding Semler Scientific's conduct to come forward [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In KBR To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in KBR between May 6, 2025 and June 19, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) HaloMD was achieving lucrative arbitration results for Nutex by engaging in a ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by October 14, 2025 [2][4]. Group 1: Company Overview - Unicycive Therapeutics, Inc. is a company listed on NASDAQ under the ticker UNCY [2]. - The firm Faruqi & Faruqi has a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. Group 2: Allegations and Stock Performance - The complaint against Unicycive alleges that the company and its executives made false or misleading statements regarding their readiness to meet FDA manufacturing compliance requirements and the regulatory prospects of their OLC NDA [4]. - Following a press release on June 10, 2025, regarding FDA deficiencies, Unicycive's stock price dropped by $3.68 per share, a decline of 40.89%, closing at $5.32 per share [5]. - On June 30, 2025, after the FDA issued a Complete Response Letter citing the same deficiencies, the stock fell by $2.03 per share, or 29.85%, closing at $4.77 per share [6]. Group 3: Legal Proceedings - Investors who suffered losses exceeding $50,000 between March 29, 2024, and June 27, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - The role of lead plaintiff in the class action is open to any member of the putative class, with the ability to direct and oversee the litigation [7].

Group 1 - The article discusses the encouragement from Faruq & Faruq, LLP for investors who suffered losses exceeding $75,000 in LifeMD to reach out for legal options [1] - The specified time frame for the losses is between May 7, 2025, and August 5, 2025 [1] - Contact information for legal inquiries is provided, including phone numbers for direct communication with partner Josh Wilson [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Quantum Corporation due to allegations of improper revenue recognition and subsequent financial restatements, which have led to significant stock price declines and investor losses [2][4][5]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi, LLP is encouraging investors who suffered losses exceeding $75,000 in Quantum Corporation between November 15, 2024, and August 18, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Quantum Corporation, with a deadline of November 3, 2025, for investors to seek the role of lead plaintiff [2]. - The lawsuit claims that Quantum Corporation made false and misleading statements regarding its revenue recognition and internal controls, which materially misled investors [4]. Group 2: Financial Disclosures and Stock Performance - On June 30, 2025, Quantum disclosed its inability to timely file its annual financial report due to a review of its accounting practices, resulting in a stock price drop of $1.00, or 10.03%, closing at $8.97 per share [5]. - On August 8, 2025, Quantum announced that its third quarter 2024 financial statements should no longer be relied upon, leading to a restatement that decreased revenue by approximately $3.9 million [6]. - Following the announcement of its CEO's resignation on August 18, 2025, Quantum's stock price fell by $0.61, or 8.2%, closing at $6.83 per share [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Fiserv, Inc. related to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by September 22, 2025 [1][3]. Group 1: Allegations Against Fiserv - The complaint alleges that Fiserv and its executives made false or misleading statements regarding the performance of its Clover platform, particularly in relation to forced migrations from the older Payeezy platform [3]. - It is claimed that Clover's revenue growth and gross payment volume (GPV) were artificially inflated due to these forced conversions, masking a slowdown in new merchant acquisitions [3]. - Following the forced migrations, many former Payeezy merchants reportedly switched to competitors due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's GPV growth [3]. Group 2: Market Reaction - On April 24, 2025, Fiserv reported a GPV growth of only 8% for Q1 2025, a significant decline from the previous year's growth rates of 14-17%, resulting in an 18.5% drop in stock price [4]. - Further disappointing disclosures on May 15, 2025, indicated continued deceleration in GPV growth, causing an additional 16.2% decline in stock price [4]. - On July 23, 2025, Fiserv lowered its full-year organic growth guidance and reported a decrease in quarterly organic revenue growth in the Merchant segment to 9% year-over-year from 11%, leading to a 13.9% drop in stock price [4].

Group 1 - The core point of the article is that Elon Musk has filed a motion to dismiss the lawsuit brought by the U.S. Securities and Exchange Commission (SEC) regarding his Twitter holdings from 2022 [1] Group 2 - The lawsuit pertains to Musk's ownership stake in Twitter, which was a significant event in the financial and tech sectors [1] - The court documents reveal Musk's legal strategy in response to regulatory scrutiny, highlighting ongoing tensions between high-profile executives and regulatory bodies [1] - This case may have implications for how similar cases are handled in the future, particularly concerning disclosures and ownership stakes in publicly traded companies [1]

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. due to allegations of misleading statements regarding the company's growth and the impact of its CEO's health on business performance [1][4]. Company Performance - C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing these issues to "the reorganization with new leadership" and the CEO's health problems [5]. - Following the announcement, C3.ai's stock price dropped from $22.13 per share on August 8, 2025, to $16.47 per share on August 11, 2025, marking a decline of approximately 25.58% in just one day [6]. Legal Proceedings - The class action lawsuit, John Liggett Sr. v. C3.ai, Inc., was initiated in the United States District Court for the Northern District of California, targeting individuals who purchased C3.ai securities between February 26, 2025, and August 8, 2025 [1][4]. - Investors who suffered losses in C3.ai securities have until October 21, 2025, to request to be appointed as lead plaintiff in the case [6].